Pre-made Apolizumab benchmark antibody (Whole mAb, anti-HLA-DRB/HLA-DRB1 therapeutic antibody, Anti-DRB1/SS1 Antibody) for drug discovery and mechanism of action (MOA) research

Anti-HLA-DRB/HLA-DRB1 therapeutic antibody (Pre-made Apolizumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Apolizumab is a humanized monoclonal antibody intended for use in hematologic cancers.[1][2] Development was abandoned in 25 because of toxic effects and lack of efficacy in human patients. The observed dose limiting toxic effects were aseptic meningitis and hemolytic uremia.[3] There are no current clinical trials into its use.[4]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-736-1mg	1mg	3090
GMP-Bios-INN-736-10mg	10mg	Inquiry
GMP-Bios-INN-736-100mg	100mg	Inquiry
GMP-Bios-INN-736-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Apolizumab Biosimilar, Whole Mab, Anti-HLA-DRB/HLA-DRB1 Antibody: Anti-DRB1/SS1 therapeutic antibody
INN Name	Apolizumab
Target	HLA-DRB/HLA-DRB1
Format	Whole mAb
Derivation	Humanized
Species Reactivity	human
CH1 Isotype	IgG1 - nd
VD LC	IgG1 - nd
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	PDL (Protein Design Labs) BioPharma (Fremont CA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0